• Users Online: 189
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2023  |  Volume : 7  |  Issue : 1  |  Page : 16-19

Role of topical intranasal corticosteroid for treatment of post-COVID olfactory dysfunction – Our experiences


Department of Otorhinolaryngology and Head and Neck Surgery, IMS and SUM Hospital, Siksha "O" Anusandhan University, Bhubaneswar, Odisha, India

Correspondence Address:
Prof. Santosh Kumar Swain
Department of Otorhinolaryngology and Head and Neck Surgery, IMS and SUM Hospital, Siksha "O" Anusandhan University, K8, Kalinga Nagar, Bhubaneswar - 751 003, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mtsm.mtsm_5_22

Rights and Permissions

Background: The coronavirus disease 2019 (COVID-19) is a highly contagious acute respiratory disease caused by a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 infection presents with respiratory illness and even respiratory failure and death. Olfactory dysfunction is an important clinical manifestation that has an impact on quality of life. Objective: This study is designed to analyze the role of the topical nasal corticosteroid in post-COVID olfactory dysfunction. Materials and Methods: This is a prospective and descriptive study on 72 COVID-19 patients who were administered topical intranasal corticosteroids and olfactory training. All of them were diagnosed with COVID-19 infection by reverse transcription–polymerase chain reaction of the nasopharyngeal swab. The detailed clinical examination and treatment with intranasal corticosteroid and its outcome were analyzed. Results: In this study, 46 (63.88%) patients were male and 26 (36.11%) were female with a male-to-female ratio of 1.76:1. The age ranges from 18 to 58 years. There were 30 (41.66%) patients in the age range of 18–30 years and 42 (58.33%) patients in the age range of 31–58 years. Out of 72 patients, 11 (15.27%) patients recovered after 2 weeks, 34 (47.22%) patients recovered after 3 weeks, and 20 (27.77%) recovered after 4 weeks. Three patients lost to follow-up during the treatment period. Conclusion: COVID-19 infection is spreading quickly all the continents of the world. Olfactory dysfunction is an important symptom of the COVID-19 infection. Intranasal mometasone spray and olfactory training are useful treatment options for post-COVID olfactory dysfunction.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed188    
    Printed2    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal